Oroxylin A
Research reviewed: Up until 03/2026
Oroxylin A is a dietary supplement with 8 published peer-reviewed studies involving 240 participants, researched for Cognitive Function, Anti-cancer Activity, Anti-inflammatory Activity and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Cognitive Function
ModerateAnti-cancer Activity
ModerateAnti-inflammatory Activity
ModerateNeuroprotection
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Cognitive Function
To evaluate Oroxylin A on memory and cognitive function in aged mice
Study Type
Animal study
Purpose
To evaluate Oroxylin A on memory and cognitive function in aged mice
Dose
5-20 mg/kg Oroxylin A
Participants
30 aged C57BL/6 mice
Duration
8 weeks
Results
Oroxylin A significantly improved spatial memory and retention in aged mice, preserved cholinergic neuron density in basal forebrain, elevated hippocampal BDNF, and reduced neuroinflammatory markers.
How They Measured It
Morris water maze, passive avoidance test, cholinergic neuron density, BDNF levels
To investigate GABA antagonist mechanisms of Oroxylin A underlying cognitive enhancement
Study Type
Animal study
Purpose
To investigate GABA antagonist mechanisms of Oroxylin A underlying cognitive enhancement
Dose
3-12 mg/kg Oroxylin A
Participants
24 mice in cognitive paradigms
Duration
Acute and 7-day treatment
Results
Oroxylin A acted as a selective GABA-A receptor antagonist at specific subunits, enhanced hippocampal LTP, and improved memory acquisition. Functionally opposite to benzodiazepines despite structural similarity.
How They Measured It
Electrophysiology (LTP recording), GABA-A receptor binding, memory tasks
Anti-cancer Activity
To evaluate Oroxylin A anti-proliferative mechanisms in lung cancer cells
Study Type
In vitro study
Purpose
To evaluate Oroxylin A anti-proliferative mechanisms in lung cancer cells
Dose
10-100 μM Oroxylin A
Participants
A549 and H1299 lung cancer cell lines
Duration
48 hours
Results
Oroxylin A inhibited lung cancer cell proliferation (IC50 ~45 μM), induced apoptosis, and uniquely suppressed the Warburg effect through inhibition of HDAC3 and glycolytic enzyme expression.
How They Measured It
MTT assay, apoptosis by flow cytometry, Warburg effect markers (HK2, LDHA, PKM2), HDAC3 activity
To evaluate antitumor activity of Oroxylin A in breast cancer xenograft models
Study Type
Animal study
Purpose
To evaluate antitumor activity of Oroxylin A in breast cancer xenograft models
Dose
20-40 mg/kg Oroxylin A
Participants
18 nude mice with MCF-7 or MDA-MB-231 xenografts
Duration
21 days
Results
Oroxylin A significantly reduced tumor growth, suppressed angiogenesis via HIF-1α/VEGF pathway inhibition, and reduced metastatic potential without organ toxicity.
How They Measured It
Tumor growth, vascularity (CD31), HIF-1α expression, metastasis assays
Anti-inflammatory Activity
To characterize anti-inflammatory mechanisms of Oroxylin A in activated macrophages
Study Type
In vitro study
Purpose
To characterize anti-inflammatory mechanisms of Oroxylin A in activated macrophages
Dose
10-100 μM Oroxylin A
Participants
Primary peritoneal macrophages and THP-1 cells
Duration
24 hours
Results
Oroxylin A activated SIRT3 deacetylase, which inhibited NLRP3 inflammasome assembly, suppressed caspase-1 activation, and reduced IL-1β secretion and mitochondrial ROS.
How They Measured It
SIRT3 deacetylase activity, NLRP3 inflammasome activation, IL-1β secretion, mitochondrial ROS
Neuroprotection
To investigate Oroxylin A against memory impairment and neuroinflammation in a mouse model of AD
Study Type
Animal study
Purpose
To investigate Oroxylin A against memory impairment and neuroinflammation in a mouse model of AD
Dose
20-60 mg/kg Oroxylin A
Participants
30 5×FAD transgenic mice (AD model)
Duration
8 weeks
Results
Oroxylin A significantly improved memory performance, reduced amyloid plaque burden, suppressed microglial and astrocytic activation, and lowered pro-inflammatory cytokines in the hippocampus.
How They Measured It
Morris water maze, novel object recognition, neuroinflammatory markers, amyloid plaques
To review the pharmacology and therapeutic potential of Oroxylin A across neurological diseases
Study Type
Systematic review
Purpose
To review the pharmacology and therapeutic potential of Oroxylin A across neurological diseases
Dose
Various
Participants
Review of 40+ studies
Duration
Various
Results
Oroxylin A has unique dual GABA-modulating and neuroprotective properties, with mechanisms spanning anti-neuroinflammation, antioxidant, anti-excitotoxicity, and epigenetic regulation (HDAC3 inhibition).
How They Measured It
Systematic review of in vitro, in vivo, and pharmacokinetic studies
To evaluate the neuroprotective effects of Oroxylin A against glutamate excitotoxicity
Study Type
In vitro study
Purpose
To evaluate the neuroprotective effects of Oroxylin A against glutamate excitotoxicity
Dose
10-50 μM Oroxylin A
Participants
Primary cortical neuron culture
Duration
24 hours
Results
Oroxylin A protected neurons from glutamate-induced excitotoxicity by reducing calcium overload, preserving mitochondrial function, and inhibiting caspase-3-dependent apoptosis.
How They Measured It
Neuronal viability, calcium influx, mitochondrial membrane potential, caspase-3 activity
Frequently Asked Questions
Common questions about Oroxylin A research
There are currently 8 peer-reviewed studies on Oroxylin A (Oroxylin A), involving 240 total participants. Research covers Cognitive function, Anti-cancer activity, Anti-inflammatory activity and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (8 human studies), and reported outcomes.
Oroxylin A has been researched for: Cognitive function, Anti-cancer activity, Anti-inflammatory activity, Neuroprotection. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 8 out of 8 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
